G00031MO

Summary
GlyTouCan ID
G00031MO
IUPAC Condensed
Gal(b1-3)GalNAc(a1-
Motifs
O-Glycan core 1 T antigen TF antigen
Subsumption Level
Fully-defined saccharide
Monoisotopic Mass
383.14
BCSDB
GlyConnect structure
GlyGen
GlycoChemExplorer
GlycoEpitope
JCGGDB AIST
KEGG GLYCAN
UniCarbKB
ChEBI
PubChem Compound
PubChem Substance
3D Structures
GlycoNAVI
G00031MO
GlycoShape
G00031MO
GLYCAM
DGalpb1-3DGalpNAca1-OH
Organisms
Taxonomic Hierarchy
GlycoGene Database (GGDB)
Displaying entries 1 - 5 of 10 in total
Gene Symbol Donor Acceptor Reducing terminal(Acceptor) Product Reducing terminal(Product) Reference
C1GALT1 (not applicable)
G57321FI
Ser/Thr
G00031MO
Ser/Thr
ST3GAL2 CMP-Neu5Ac
G00031MO
R
G65562ZE
R
ST3GAL1 CMP-Neu5Ac
G00031MO
Thr
G65562ZE
Thr
ST6GALNAC1 CMP-Neu5Ac
G00031MO
Ser/Thr
G56682BC
Ser/Thr
ST3GAL4 CMP-Neu5Ac
G00031MO
free
G65562ZE
free
Displaying entries 1 - 5 of 32 in total
Gene Symbol Donor Acceptor Reducing terminal(Acceptor) Product Reducing terminal(Product) Reference
C1GALT1 (not applicable)
G57321FI
Ser/Thr
G00031MO
Ser/Thr
ST3GAL2 CMP-Neu5Ac
G00031MO
R
G65562ZE
R
ST3GAL1 CMP-Neu5Ac
G00031MO
Thr
G65562ZE
Thr
ST6GALNAC1 CMP-Neu5Ac
G00031MO
Ser/Thr
G56682BC
Ser/Thr
ST3GAL1 CMP-Neu5Ac
G00031MO
Antifreeze glycoprotein
G65562ZE
Antifreeze glycoprotein
Displaying entries 1 - 5 of 14 in total
Gene Symbol Donor Acceptor Reducing terminal(Acceptor) Reference
ST6GAL2 CMP-Neu5Ac
G00031MO
benzyl
ST6GAL2 CMP-Neu5Ac
G00031MO
free
ST3GAL3 CMP-Neu5Ac
G00031MO
Antifreeze glycoprotein
ST3GAL6 CMP-Neu5Ac
G00031MO
free
ST6GALNAC2 CMP-Neu5Ac
G00031MO
benzyl
GlycoEpitope
Epitope ID
EP0020
Epitope Name
T Antigen
Pathway
Displaying all 8 entries
Pathway Name Organism
E.coli O107 Escherichia coli
E.coli O117 Escherichia coli
E.coli O185 Escherichia coli
E.coli O5ab Escherichia coli
E.coli O5ac Escherichia coli
E.coli O70 Escherichia coli
E.coli O71 Escherichia coli
E.coli O83 Escherichia coli
Sequence Descriptors
GlycoCT
RES
1b:a-dgal-HEX-1:5
2s:n-acetyl
3b:b-dgal-HEX-1:5
LIN
1:1d(2+1)2n
2:1o(3+1)3d
WURCS
WURCS=2.0/2,2,1/[a2112h-1a_1-5_2*NCC/3=O][a2112h-1b_1-5]/1-2/a3-b1
Literature (from GlyTouCan)
BCSDB
GlycoEpitope
PubAnnotation
Displaying entries 1 - 5 of 10 in total
Title Authors Source Publication Date PubMed ID
Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation.
  • Wang L
  • Liu R
  • Ye P
  • Wong C
  • Chen GY
  • Zhou P
  • Sakabe K
  • Zheng X
  • Wu W
  • Zhang P
  • Jiang T
  • Bassetti MF
  • Jube S
  • Sun Y
  • Zhang Y
  • Zheng P
  • Liu Y
Nat Commun 2015 Jan 20 25600590
Loss of Core 1-derived O-Glycans Decreases Breast Cancer Development in Mice.
  • Song K
  • Herzog BH
  • Fu J
  • Sheng M
  • Bergstrom K
  • McDaniel JM
  • Kondo Y
  • McGee S
  • Cai X
  • Li P
  • Chen H
  • Xia L
J Biol Chem 2015 Aug 14 26124270
Sialome analysis of the cephalochordate Branchiostoma belcheri, a key organism for vertebrate evolution.
  • Guérardel Y
  • Chang LY
  • Fujita A
  • Coddeville B
  • Maes E
  • Sato C
  • Harduin-Lepers A
  • Kubokawa K
  • Kitajima K
Glycobiology 2012 Apr 22057003
Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
  • Tsuiji H
  • Takasaki S
  • Sakamoto M
  • Irimura T
  • Hirohashi S
Glycobiology 2003 Jul 12672699
Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125.
  • Kui Wong N
  • Easton RL
  • Panico M
  • Sutton-Smith M
  • Morrison JC
  • Lattanzio FA
  • Morris HR
  • Clark GF
  • Dell A
  • Patankar MS
J Biol Chem 2003 Aug 1 12734200

About Release Notes Help Feedback

International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.1.1

Last updated: February 17, 2025